Insight Molecular Diagnostics Inc. — Director's Dealing 2022

Aug 17, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oncocyte Corp (OCX)
CIK: 0001642380
Period of Report: 2022-08-15

Reporting Person: KINGSLEY ALFRED D (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-08-15	Common Stock, no par value	A	10000	—	Acquired	404111	Direct
2022-08-15	Common Stock, no par value	P	5000	$0.97	Acquired	409111	Direct
2022-08-15	Common Stock, no par value	P	5000	$0.97	Acquired	414111	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-08-15	Option to Purchase Common Stock	$0.97	A	45000	Acquired	2032-08-15	Common Stock (45000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, no par value	75345	Indirect
Common Stock, no par value	18767	Indirect

Footnotes

F1: The Restricted Stock Units shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.

F2: The shares of common stock are held by Greenbelt Corp. The Reporting Person is the President of Greenbelt Corp. and in such capacity has the right to vote and dispose of the securities held by such entity.

F3: The shares of common stock are held by Greenway Partners, LP. The Reporting Person is the General Partner of Greenway Partners, LP and in such capacity has the right to vote and dispose of the securities held by such entity.

F4: Options shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.